Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 837-845

  Soliman, Nema Ali ^a   Zineldeen, Doaa Hussein ^a   El Khadrawy, Osama Helmy ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Breast cancer; IL 12; IL 6; NUCKS 1; Obesity

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LCN2 PROTEIN, HUMAN; LIPOCALIN; NUCKS PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER GRADING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; OBESITY; PROGNOSIS;

ACUTE-PHASE PROTEINS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-10; INTERLEUKIN-6; LIPOCALINS; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR PROTEINS; OBESITY; PHOSPHOPROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894648221     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.837     Document Type: Article

References (60)

1. Abdelsalam KE, Hassan IK, Sadig IA (2012). The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci, 17, 562-5.
2. Auguet T, Quintero Y, Terra X, et al (2011). Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity, 19, 2295-300
3. Barton BE, Murphy TF (2001). Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine, 16, 251-7.
4. Bauer M, Eickhoff JC, Gould MN, et al (2008). Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat, 108, 389-97.
5. Cejas P, Casado E, Belda-Iniesta C, et al (2004). Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control, 15, 707-19.
6. Cramer EP, Glenthoj A, Häger M, et al (2012). No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancer. PLoS One, 7, 39646-59.
7. Dandona P, Aljada A, Bandyopadhyay A, et al (2004). Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol, 25, 4-7.
8. Derin D, Soydinc HO, Guney N, et al (2007). Serum IL-8 and IL-12 levels in breast cancer. Med Oncol, 24, 163-8.
9. Drosos Y, Kouloukoussa M, Ostvold AC, et al (2009). NUCKS overexpression in breast cancer. Cancer Cell Int, 9, 19-33.
10. Duseja A, Thumburu KK, Das A, et al (2007). Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol, 26, 170-3.
11. El-Kadre LJ, Tinoco AC (2013). Interleukin-6 and obesity: the crosstalk between intestine, pancreas and liver. Curr Opin Clin Nutr Metab Care, 16, 564-8.
12. Fernandez SV, Robertson FM, Pei J, et al (2013). Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat, 140, 23-33.
13. Friedewald WT, Levy RI, Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18, 499-502.
14. Gaudet MM, Patel AV, Teras LR, et al (2013). Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet, 4, 156-66.
15. Giri D, Ozen M, Ittmann M (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol, 159, 2159-65.
16. Gonullu G, Ersoy C, Ersoy A, et al (2005). Relation between insulin resistance and serum concentrations of IL-6 and TNF-alpha in overweight or obese women with early stage breast cancer. Cytokine, 31, 264-9.
17. Goodwin PJ, Ennis M, Pritchard KI, et al (2002). Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol, 20, 42-51.
18. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature, 434, 907-13.
19. Goyal R, Faizy AF, Siddiqui SS, Singhai M (2012). Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: Pre-and postinsulin effects. N Am J Med Sci, 4, 180-4.
20. Grundt K, Haga IV, Aleporou-Marinou V, et al (2004). Characterisation of the NUCKS gene on human chromosome 1q32.1 and the presence of a homologous gene in different species. Biochem Biophys Res Commun, 323, 796-801.
21. Haura EB, Turkson J, Jove R (2005). Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol, 2, 315-24.
22. Hsu IR, Kim SP, Kabir M, et al (2007). Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr, 86, 867-71.
23. Huffman DM, Barzilai N (2009). Role of visceral adipose tissue in aging. Biochim Biophys Acta, 1790, 1117-23.
24. Hussein MZ, Al Fikky A, Abdel Bar I, et al (2004). Serum IL-6 and IL-12 levels in breast cancer patients. Egypt J Immunol, 11, 165-70.
25. Jones C, Mackay A, Grigoriadis A, et al (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Res, 64, 3037-45.
26. Kedzierska M, Olas B, Wachowicz B, et al (2010). The lipid peroxidation in breast cancer patients. Gen Physiol Biophys, 29, 208-10.
27. Law IK, Xu A, Lam KS, et al (2010). Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes, 59, 872-82.
28. Ligibel J (2011). Obesity and breast cancer. Oncology (Williston Park), 25, 994-1000.
29. Liu R, Wang X, Chen GY, et al (2007). The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells. N Engl J Med, 356, 217-26.
30. Liu X, Hamnvik OP, Petrou M, et al (2011). Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study. Eur J Endocrinol, 165, 805-12.
31. Matsuoka S, Ballif BA, Smogorzewska A, et al (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science, 316, 1138-9.
32. Minamino T, Yoshida T, Tateno K, et al (2003). Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation, 108, 2264-9.
33. Moschos SJ, Mantzoros CS (2002). The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 63, 317-32.
34. Naylor TL, Greshock J, Wang Y, et al (2005). High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res, 7, 1186-98.
35. Nguyen DX, Massagué J (2007). Genetic determinants of cancer metastasis. Nat Rev Genet, 8, 341-52.
36. Nyante SJ, Devries S, Chen YY, et al (2004). Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. Hum Pathol, 35, 759-63.
37. Olsson N, Carlsson P, James P, et al (2013). Grading breast cancer tissues using molecular portraits. Mol Cell Proteomics, 12, 3612-23.
38. Ostvold AC, Norum JH, Mathiesen S, et al (2001). Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem, 268, 2430-40.
39. Parker ED, Folsom AR (2003). Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study. Int J Obes Relat Metab Disord, 27, 1447-52.
40. Parkin DM, Fernández LM (2006). Use of statistics to assess the global burden of breast cancer. Breast J, 12, 70-80.
41. Robbins P, Pinder S, de Klerk N, et al (1995). Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol, 26, 873-9.
42. Roy R, Wewer UM, Zurakowski D, et al (2004). ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem, 279, 51323-30.
43. Salgado R, Benoy I, Weytjens R, et al (2002). Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer, 87, 1437-44.
44. Sargent LM, Ensell MX, Ostvold AC, et al (2008). Chromosomal changes in high-and low-invasive mouse lung adenocarcinoma cell strains derived from early passage mouse lung adenocarcinoma cell strains. Toxicol Appl Pharmacol, 233, 81-91.
45. Sharabiani MT, Vermeulen R, Scoccianti C, et al (2011). Immunologic profile of excessive body weight. Biomarkers, 16, 243-51.
46. Silswal N, Singh AK, Aruna B, et al (2005). Human resistin stimulate the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun, 334, 1092-101.
47. Smyth MJ, Cretney E, Kershaw MH, et al (2004). Cytokines in cancer immunity and immunotherapy. Immunol Rev, 202, 275-93.
48. Strissel KJ, DeFuria J, Shaul ME, et al (2010). T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity (Silver Spring), 18, 1918-25.
49. Suárez-álvarez K, Solís-Lozano L, Leon-Cabrera S, et al (2013). Serum IL-12 is increased in Mexican obese subjects and associated with low-grade inflammation and obesity-related parameters. Mediators Inflamm, 2013, 967067.
50. Surendar J, Mohan V, Rao MM, et al (2011). Increased levels of both Th1 and Th2 cytokines in subjects with metabolic syndrome (CURES-103). Diabetes Technol Ther, 13, 477-82.
51. Trinchieri G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 3, 133-46.
52. Wang Y, Lam KS, Kraegen EW, et al (2007). Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem, 53, 34-41.
53. Wiese C, Dray E, Groesser T, et al (2007). Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol Cell, 28, 482-90.
54. Wiśniewski JR, Zougman A, Krüger S, et al (2008). Constitutive and dynamic phosphorylation and acetylation sites on NUCKS, a hypermodified nuclear protein, studied by quantitative proteomics. Proteins, 73, 710-8.
55. Wu HP, Kuo SF, Wu SY et al (2010). High interleukin-12 production from stimulated peripheral blood mononuclear cells of type 2 diabetes patients. Cytokine, 51, 298-304.
56. Xiaohong L, Yun W, Ralph BA (2011). Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol, 226, 309-14.
57. Xu J, Chen Y, Olopade OI (2010). MYC and Breast Cancer. Genes Cancer, 1, 629-40.
58. Yang J, Bielenberg DR, Rodig SJ, et al (2009). Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA, 106, 3913-8.
59. Yang J, McNeish B, Butterfield C, et al (2013). Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J, 27, 45-50.
60. Zavala G, Long KZ, García OP, et al (2012). Specific micronutrient concentrations are associated with inflammatory cytokines in a rural population of Mexican women with a high prevalence of obesity. Br J Nutr, 29, 1-9.